Compare Merck & Co., Inc. (MRK) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Value Index Fund ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Vanguard Value Index Fund ETF trades at $225. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals.
| MRK | VTV | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | — |
52-Week High | $156.43 | $227.51 |
52-Week Low | $77.60 | $182.86 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
VTV, the Vanguard Value ETF, trades at $224.64, down 0.8% on the day, with technical indicators showing a neutral overall signal amid mixed moving average and oscillator readings. The fund's value-focused strategy has outperformed growth counterparts in 2026, attracting institutional inflows, though key financial ratios are not individually disclosed for the ETF. A dividend of $1.08 is scheduled for June 2026.
The outlook for VTV is supported by the ongoing rotation into value stocks, with media highlighting its 2026 strength versus growth ETFs. Risks include potential underperformance if growth resumes leadership and fee-related long-term tracking differences noted in analysis. The neutral technical stance suggests near-term consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
